Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Cryptotanshinone targets tumor-initiating cells through down-regulation of stemness genes expression.

Zhang Y, Cabarcas SM, Zheng JI, Sun L, Mathews LA, Zhang X, Lin H, Farrar WL.

Oncol Lett. 2016 Jun;11(6):3803-3812. Epub 2016 Apr 15.

2.

Genomic Analysis of Invasive Human Bone Marrow Derived Mesenchymal Stem Cells.

Mathews LA, Hurt EM, Zhang X, Farrar WL.

J Bone Marrow Res. 2013 May 23;1:122.

3.

Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer.

Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, Wang Y, Lin D, Lam WL, Farrar WL, Isogai T, Morant R, Castori-Eppenberger S, Chi KN, Wang Y, Helgason CD.

Oncotarget. 2014 Feb 15;5(3):764-74.

4.

Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells.

Sun L, Mathews LA, Cabarcas SM, Zhang X, Yang A, Zhang Y, Young MR, Klarmann KD, Keller JR, Farrar WL.

Stem Cells. 2013 Aug;31(8):1454-66. doi: 10.1002/stem.1394.

5.

The differentiation of pancreatic tumor-initiating cells by vitronectin can be blocked by cilengitide.

Cabarcas SM, Sun L, Mathews L, Thomas S, Zhang X, Farrar WL.

Pancreas. 2013 Jul;42(5):861-70. doi: 10.1097/MPA.0b013e318279d568.

6.

Histone lysine demethylases in breast cancer.

Paolicchi E, Crea F, Farrar WL, Green JE, Danesi R.

Crit Rev Oncol Hematol. 2013 May;86(2):97-103. doi: 10.1016/j.critrevonc.2012.11.008. Epub 2012 Dec 23.

7.

Embryonic stem cell pathways and chemotherapy response: an unexplored route.

Duhagon MA, Crea F, Danesi R, Farrar WL.

Ann Oncol. 2013 Feb;24(2):558-9. doi: 10.1093/annonc/mds610. Epub 2012 Dec 11. No abstract available.

PMID:
23233652
8.

The emerging role of histone lysine demethylases in prostate cancer.

Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, Helgason CD.

Mol Cancer. 2012 Aug 6;11:52. doi: 10.1186/1476-4598-11-52. Review.

9.

EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis.

Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A, Danesi R.

Cancer Metastasis Rev. 2012 Dec;31(3-4):753-61. doi: 10.1007/s10555-012-9387-3. Review.

PMID:
22711031
10.

Long-term recovery of irradiated prostate cancer increases cancer stem cells.

Cho YM, Kim YS, Kang MJ, Farrar WL, Hurt EM.

Prostate. 2012 Dec 1;72(16):1746-56. doi: 10.1002/pros.22527. Epub 2012 Apr 18.

PMID:
22513891
11.

The role of upregulated miRNAs and the identification of novel mRNA targets in prostatospheres.

Cabarcas SM, Thomas S, Zhang X, Cherry JM, Sebastian T, Yerramilli S, Lader E, Farrar WL, Hurt EM.

Genomics. 2012 Feb;99(2):108-17. doi: 10.1016/j.ygeno.2011.11.007. Epub 2011 Dec 20.

12.

An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.

Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, Salvatore L, Cremolini C, Schirripa M, Graziano F, Ronzoni M, Ricci V, Farrar WL, Falcone A, Danesi R.

Ann Oncol. 2012 May;23(5):1207-13. doi: 10.1093/annonc/mdr387. Epub 2011 Sep 16.

PMID:
21926398
13.

The cancer stem cell niche--there goes the neighborhood?

Cabarcas SM, Mathews LA, Farrar WL.

Int J Cancer. 2011 Nov 15;129(10):2315-27. doi: 10.1002/ijc.26312. Epub 2011 Sep 14. Review.

14.

Increased expression of DNA repair genes in invasive human pancreatic cancer cells.

Mathews LA, Cabarcas SM, Hurt EM, Zhang X, Jaffee EM, Farrar WL.

Pancreas. 2011 Jul;40(5):730-9. doi: 10.1097/MPA.0b013e31821ae25b.

15.

Pharmacogenomics and cancer stem cells: a changing landscape?

Crea F, Duhagon MA, Farrar WL, Danesi R.

Trends Pharmacol Sci. 2011 Aug;32(8):487-94. doi: 10.1016/j.tips.2011.03.010. Epub 2011 Apr 27. Review.

16.

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.

Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R, Farrar WL.

Mol Cancer. 2011 Apr 18;10:40. doi: 10.1186/1476-4598-10-40.

17.

DNA repair: the culprit for tumor-initiating cell survival?

Mathews LA, Cabarcas SM, Farrar WL.

Cancer Metastasis Rev. 2011 Jun;30(2):185-97. doi: 10.1007/s10555-011-9277-0. Review.

18.

Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease.

Cabarcas SM, Hurt EM, Farrar WL.

Curr Mol Med. 2010 Nov;10(8):744-55. Review.

19.

Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells.

Mathews LA, Hurt EM, Zhang X, Farrar WL.

Mol Cancer. 2010 Oct 7;9:267. doi: 10.1186/1476-4598-9-267.

20.

Clinical significance of Polycomb gene expression in brain tumors.

Crea F, Hurt EM, Farrar WL.

Mol Cancer. 2010 Sep 30;9:265. doi: 10.1186/1476-4598-9-265.

21.

Survivin is not induced by novel taxanes.

Sharifi N, Qi J, Bane S, Sharma S, Li R, Robey R, Figg WD, Farrar WL, Kingston DG.

Mol Pharm. 2010 Dec 6;7(6):2216-23. doi: 10.1021/mp100211k. Epub 2010 Oct 7. Erratum in: Mol Pharm. 2011 Feb 7;8(1):315.

22.

BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.

Crea F, Duhagon Serrat MA, Hurt EM, Thomas SB, Danesi R, Farrar WL.

Int J Cancer. 2011 Apr 15;128(8):1946-54. doi: 10.1002/ijc.25522.

23.

Genomic profiling of tumor initiating prostatospheres.

Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, Farrar WL.

BMC Genomics. 2010 May 25;11:324. doi: 10.1186/1471-2164-11-324.

24.

Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells.

Volate SR, Kawasaki BT, Hurt EM, Milner JA, Kim YS, White J, Farrar WL.

Mol Cancer Ther. 2010 Feb;9(2):461-70. doi: 10.1158/1535-7163.MCT-09-0507. Epub 2010 Feb 2.

25.

Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation.

Hurt EM, Chan K, Serrat MA, Thomas SB, Veenstra TD, Farrar WL.

Stem Cells. 2010 Mar 31;28(3):390-8. doi: 10.1002/stem.271.

26.

Targeting prostate cancer stem cells.

Crea F, Mathews LA, Farrar WL, Hurt EM.

Anticancer Agents Med Chem. 2009 Dec;9(10):1105-13. Review.

PMID:
19925394
27.

Cancer stem cell epigenetics and chemoresistance.

Crea F, Danesi R, Farrar WL.

Epigenomics. 2009 Oct;1(1):63-79. doi: 10.2217/epi.09.4. Review.

PMID:
22122637
28.

Epigenetic gene regulation in stem cells and correlation to cancer.

Mathews LA, Crea F, Farrar WL.

Differentiation. 2009 Jul;78(1):1-17. doi: 10.1016/j.diff.2009.04.002. Epub 2009 May 14. Review.

29.

Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature.

Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL.

Clin Exp Metastasis. 2009;26(5):433-46. doi: 10.1007/s10585-009-9242-2. Epub 2009 Feb 17.

30.

Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach.

Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, Farrar WL.

Prostate. 2009 Jun 1;69(8):827-37. doi: 10.1002/pros.20931.

31.

Targeting cancer stem cells with phytochemicals.

Kawasaki BT, Hurt EM, Mistree T, Farrar WL.

Mol Interv. 2008 Aug;8(4):174-84. doi: 10.1124/mi.8.4.9. Review.

PMID:
18829843
32.

Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation.

Qin HR, Kim HJ, Kim JY, Hurt EM, Klarmann GJ, Kawasaki BT, Duhagon Serrat MA, Farrar WL.

Cancer Res. 2008 Oct 1;68(19):7736-41. doi: 10.1158/0008-5472.CAN-08-1125.

33.

Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.

Sharifi N, Hurt EM, Thomas SB, Farrar WL.

Clin Cancer Res. 2008 Oct 1;14(19):6073-80. doi: 10.1158/1078-0432.CCR-08-0591.

34.

Cancer stem cells, CD200 and immunoevasion.

Kawasaki BT, Farrar WL.

Trends Immunol. 2008 Oct;29(10):464-8. doi: 10.1016/j.it.2008.07.005. Epub 2008 Sep 3.

PMID:
18775673
35.

Cancer stem cells: the seeds of metastasis?

Hurt EM, Farrar WL.

Mol Interv. 2008 Jun;8(3):140-2. doi: 10.1124/mi.8.3.7. No abstract available.

PMID:
18693193
36.

A Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer.

Yang XY, Wang LH, Farrar WL.

PPAR Res. 2008;2008:961753. doi: 10.1155/2008/961753. Retraction in: Ppar Research. PPAR Res. 2015;2015:982750.

37.

Epigenetic gene silencing in the Wnt pathway in breast cancer.

Klarmann GJ, Decker A, Farrar WL.

Epigenetics. 2008 Mar-Apr;3(2):59-63. Epub 2008 Mar 12. Review.

PMID:
18398311
38.

Re: "Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the women's health initiative (United States)".

Sharifi N, Farrar WL.

Am J Epidemiol. 2008 Apr 15;167(8):1016; author reply 1016. doi: 10.1093/aje/kwn040. Epub 2008 Mar 15. No abstract available.

PMID:
18344511
39.

CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.

Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL.

Br J Cancer. 2008 Feb 26;98(4):756-65. doi: 10.1038/sj.bjc.6604242. Epub 2008 Feb 12.

40.

IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase.

Hodge DR, Cho E, Copeland TD, Guszczynski T, Yang E, Seth AK, Farrar WL.

Cancer Genomics Proteomics. 2007 Nov-Dec;4(6):387-98.

41.

Androgen receptor expression in prostate cancer stem cells: is there a conundrum?

Sharifi N, Hurt EM, Farrar WL.

Cancer Chemother Pharmacol. 2008 Oct;62(5):921-3. Epub 2007 Dec 13.

PMID:
18075739
42.
43.

DNA hypermethylation and partial gene silencing of human thymine- DNA glycosylase in multiple myeloma cell lines.

Peng B, Hurt EM, Hodge DR, Thomas SB, Farrar WL.

Epigenetics. 2006 Jul-Sep;1(3):138-45. Epub 2006 May 25.

PMID:
17965616
44.

Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.

Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL.

Biochem Biophys Res Commun. 2007 Dec 28;364(4):778-82. Epub 2007 Oct 25.

45.

Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines.

Hurt EM, Thomas SB, Peng B, Farrar WL.

Br J Cancer. 2007 Oct 22;97(8):1116-23. Epub 2007 Sep 25.

46.
47.

Functional and genomic analyses of FOXP3-transduced Jurkat-T cells as regulatory T (Treg)-like cells.

Kim JY, Kim HJ, Hurt EM, Chen X, Howard OMZ, Farrar WL.

Biochem Biophys Res Commun. 2007 Oct 12;362(1):44-50. doi: 10.1016/j.bbrc.2007.07.187. Epub 2007 Aug 10.

PMID:
17706604
48.

A bifunctional colchicinoid that binds to the androgen receptor.

Sharifi N, Hamel E, Lill MA, Risbood P, Kane CT Jr, Hossain MT, Jones A, Dalton JT, Farrar WL.

Mol Cancer Ther. 2007 Aug;6(8):2328-36.

49.

15-deoxy-Delta12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain.

Kim HJ, Kim JY, Meng Z, Wang LH, Liu F, Conrads TP, Burke TR, Veenstra TD, Farrar WL.

Cancer Res. 2007 Mar 15;67(6):2595-602.

50.

TGFBR3 loss and consequences in prostate cancer.

Sharifi N, Hurt EM, Kawasaki BT, Farrar WL.

Prostate. 2007 Feb 15;67(3):301-11.

PMID:
17192875

Supplemental Content

Loading ...
Support Center